 |
|
|
|
|
|
 |
 |
 |
 |
 |
|
Elusys Therapeutics is committed to developing new biotherapeutic products that dramatically improve treatment of life-threatening infectious disease.
|
ANTHIM™ |
 |
|
 |
ETI-211 |
|
|
 |
Heteropolymer Antibodies |
 |
 |
PARTNERS >>
NEWS
Elizabeth Posillico, PhD inducted into NJ’s High Tech Hall of Fame
read more >>
April 22nd, 2008
Elusys’ Anthim™ Dramatically Improves Survival of Animals Treated...
read more >>
September 25th, 2007
NIAID / BARDA Awards Elusys a $12 Million Contract to Further Develop Anthim...
read more >>
LEARN MORE ABOUT...
Our product pipeline
New approaches for the treatment of infectious disease
learn more >>
Working at Elusys
A dynamic, creative environment to advance your career
learn more >>